Bijuva
Bijuva is the first FDA-approved oral capsule combining bioidentical estradiol and progesterone in one pill, for postmenopausal women with a uterus.
How it works
Bijuva combines bioidentical estradiol and micronized progesterone in a single capsule — the first FDA-approved combination product to do so. The clinical significance is convenience and adherence: people on estrogen plus separate progesterone must manage two prescriptions; Bijuva consolidates that into one. The clinical trial program (REPLENISH) demonstrated it is effective for vasomotor symptoms and provides adequate endometrial protection. Because it contains FDA-regulated, bioidentical hormones at validated doses, it offers the same regimen as Prometrium plus oral estradiol in a single daily capsule.
Because Bijuva contains both hormones, the combined pharmacology applies: the estradiol component drives vasomotor, mood, sleep, and tissue effects, while the progesterone component provides uterine protection and the GABA-A neurosteroid sedating effect. The combined capsule is taken at the same time each day — typically in the evening to align the progesterone sedating effect with the sleep window.
How to track Bijuva
- Hot flash frequency and severity — the primary vasomotor response indicator.
- Sleep quality — the progesterone component has a GABA-A neurosteroid sedating effect; tracking sleep separately from vasomotor control shows both dimensions of response.
- Breakthrough bleeding or spotting — even with a combined capsule, bleeding pattern is diagnostically important and should be logged with dates and description.
- Side effects from either component: breast tenderness or bloating (estradiol or progesterone), next-day grogginess (progesterone), nausea (oral estradiol).
- Dosing consistency — oral bioidentical HRT requires consistent daily timing; logging when you take it reveals any timing-related symptom patterns.
- Log the time you use Bijuva each evening — the progesterone component's sedating effect is timing-dependent, and consistent timing maximizes the sleep benefit.
- Track hot flash frequency weekly and compare to your pre-treatment baseline — the estradiol component drives vasomotor response, which typically stabilizes within two to four weeks.
- Rate sleep quality on a consistent scale each morning — this captures the progesterone's contribution independently of hot flash reduction.
- Log all breakthrough bleeding with dates and description — it is the most important safety-monitoring variable on any estrogen-plus-progestogen regimen.
- If you switch from separate prescriptions to Bijuva, use the switch date as a new baseline — even if the combined dose is nominally equivalent, the absorption profile from a single capsule may differ slightly.
Questions to ask your physician
- My hot flash frequency before starting Bijuva was [X] per day. At [N] weeks, my current average is [Y]. Is that response consistent with the REPLENISH trial data?
- My sleep quality log shows [pattern] since starting — is the progesterone component's sedating effect appearing as expected?
- I've been logging breakthrough bleeding on [dates, description] — what does that pattern suggest?
- My breast tenderness log shows [pattern] — is that consistent with estradiol dose, or does it suggest an overall dose adjustment?